CD39 is a key enzyme in removing ATP from the tumor microenvironment; increased ATP may enhance the adaptive immune response against tumors.1
CANCER CELL INTRINSIC TARGET
AXL Inhibitor (AB801)
AXL overexpression is associated with tumor resistance to chemotherapy
and immunotherapy drugs.2
References: 1. Moesta et al. Targeting CD39 in Cancer. Nat Rev Immunol. Volume 20, pages 739–755 (2020). 2. Axelrod HD, Valkenburg KC, Amend SR, et al. AXL is a putative tumor suppressor and dormancy regulator in prostate cancer. Mol Cancer Res. 2019;17(2):356-369.